New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 27, 2012
05:11 EDTPRXL, SGYPSynergy Pharmaceuticals begins Phase IIb trial of Plescanatide in IBS-C
Synergy Pharmaceuticals (SGYP) announced that dosing has commenced in a Phase IIb clinical trial of plecanatide to treat patients with constipation-predominant irritable bowel syndrome, or IBS-C. This trial is being conducted at 70 sites in the U.S. and includes 350 patients with IBS-C who will be treated with one of four doses of plecanatide or placebo, taken once daily over a period of 12 weeks. PAREXEL International (PRXL) is the Contract Research Organization for the trial.
News For SGYP;PRXL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 21, 2014
08:01 EDTPRXLPAREXEL revenue guidance looks 'aggressive,' says Jefferies
Jefferies views PAREXEL's 2015 revenue guidance as "aggressive" saying the company's backlog conversion must accelerate faster than 2014 levels just to hit the low end of the outlook. The firm keeps a Hold rating on the stock with a $57 price target.
November 19, 2014
09:16 EDTSGYPOn The Fly: Pre-market Movers
Subscribe for More Information
08:06 EDTSGYPSynergy Pharm says analysis shows Phase 2 SP-333 trial met primary endpoint
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use